Reflective of this endorsement, a 2023 systematic review showed that 72.2% of ECCO-partnered gastroenterology association guidelines in Europe support the transition of patients with IBD from an anti-TNF-α reference biologic to a biosimilar medicine [57]. This evidence concerns the gene TNF and inflammatory bowel disease.